U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C30H27N5O
Molecular Weight 473.5683
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-833923

SMILES

CNCC1=CC=C(C)C(NC(=O)C2=CC=C(NC3=NC4=C(C=CC=C4)C(=N3)C5=CC=CC=C5)C=C2)=C1

InChI

InChIKey=KLRRGBHZCJLIEL-UHFFFAOYSA-N
InChI=1S/C30H27N5O/c1-20-12-13-21(19-31-2)18-27(20)33-29(36)23-14-16-24(17-15-23)32-30-34-26-11-7-6-10-25(26)28(35-30)22-8-4-3-5-9-22/h3-18,31H,19H2,1-2H3,(H,33,36)(H,32,34,35)

HIDE SMILES / InChI

Molecular Formula C30H27N5O
Molecular Weight 473.5683
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24105601 | http://drugprofiles.informa.com/drug_profiles/14075-bms-833923

BMS-833923 was discovered by Exelixis and was out-licensed to Bristol-Myers Squibb. BMS-833923 is an orally bioavailable Smoothened antagonist. BMS-833923 reduces hedgehog pathway activity, decreases cell proliferation and induces apoptosis via the intrinsic pathway in esophageal adenocarcinoma (EAC) cell lines. BMS-833923 dose-dependently affects canonical and prostate hedgehog signature gene transcription in vitro. BMS-833923 is in phase II clinical trials for the treatment of chronic myeloid leukaemia.

Originator

Curator's Comment: BMS-833923 was discovered by Exelixis and was out-licensed to Bristol-Myers Squibb. # Exelixis

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
21.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Emerging treatments and signaling pathway inhibitors.
2011 Dec
Smoothened inhibition leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells.
2013 Aug
Patents

Sample Use Guides

Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
Route of Administration: Oral
BMS-833923 (10 uM) decreased cell proliferation of cholangiocellular carcinoma cell line (EGI-1) up to 89.4% compared to the control.
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:17:37 GMT 2023
Edited
by admin
on Sat Dec 16 05:17:37 GMT 2023
Record UNII
41J7ZJ239R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-833923
Code English
BMS-833923 [WHO-DD]
Common Name English
XL139
Code English
BMS-833923 FREE BASE ANHYDROUS
Code English
XL-139
Code English
N-(2-METHYL-5-((METHYLAMINO)METHYL)PHENYL)-4-((4-PHENYLQUINAZOLIN-2-YL)AMINO)BENZAMIDE
Systematic Name English
Code System Code Type Description
CAS
1059734-66-5
Created by admin on Sat Dec 16 05:17:37 GMT 2023 , Edited by admin on Sat Dec 16 05:17:37 GMT 2023
PRIMARY
PUBCHEM
57662985
Created by admin on Sat Dec 16 05:17:37 GMT 2023 , Edited by admin on Sat Dec 16 05:17:37 GMT 2023
PRIMARY
FDA UNII
41J7ZJ239R
Created by admin on Sat Dec 16 05:17:37 GMT 2023 , Edited by admin on Sat Dec 16 05:17:37 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY